Rare pulmonary neoplasms.
We reviewed the clinical course and the results of various treatment modalities of 80 patients with rare pulmonary neoplasms, who constituted 0.8% of all patients with primary lung cancer treated at the Mayo Clinic from 1980 through 1990. The 50 male and 30 female patients had a median age of 60 years (range, 20 to 87). The histopathologic types of these rare pulmonary neoplasms were non-Hodgkin's lymphoma (41%), carcinosarcoma (20%), mucoepidermoid carcinoma (15%), malignant fibrous histiocytoma (5%), malignant melanoma (4%), fibrosarcoma (4%), leiomyosarcoma (4%), angiosarcoma (2%), hemangiopericytoma (2%), osteosarcoma (1%), and blastoma (1%). Follow-up was complete in all 80 patients, and the median duration of follow-up was 59 months (range, 15 to 130). Of the 80 patients, 63 (79%) underwent pulmonary resection. Of the other 17 patients, 8 underwent only bronchoscopy for diagnosis, 4 had unresectable disease at thoracotomy, 3 had metastatic disease on initial assessment, and 2 had mediastinal involvement detected on mediastinoscopy. Fifty-four patients (68%) received chemotherapy or radiation treatment (or both). The overall 5-year survival was 39%. The strongest factors that influenced survival were cell type and extent of disease at time of initial examination.
Miller
D L
DL
Division of Thoracic and Cardiovascular Surgery, Mayo Clinic Rochester, Minnesota.
Allen
M S
MS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000628:therapy; D002296:Carcinosarcoma / Q000628:therapy; D005260:Female; D005354:Fibrosarcoma / Q000628:therapy; D005500:Follow-Up Studies; D006394:Hemangiosarcoma / Q000628:therapy; D018219:Histiocytoma, Benign Fibrous / Q000628:therapy; D006801:Humans; D007890:Leiomyosarcoma / Q000628:therapy; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D012516:Osteosarcoma / Q000628:therapy; D015996:Survival Rate